Abstract
We tested the hypothesis that left ventricular hypertrophy (LVH) interferes with the antithrombotic effects of dabigatran and warfarin in patients with atrial fibrillation (AF). This is a post-hoc analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) Study. We defined LVH by electrocardiography (ECG) and included patients with AF on the ECG tracing at entry. Hazard ratios (HR) for each dabigatran dose vs. warfarin were calculated in relation to LVH. LVH was present in 2353 (22.7%) out of 10 372 patients. In patients without LVH, the rates of primary outcome were 1.59%/year with warfarin, 1.60% with dabigatran 110 mg (HR vs. warfarin 1.01, 95% confidence interval (CI) 0.75-1.36) and 1.08% with dabigatran 150 mg (HR vs. warfarin 0.68, 95% CI 0.49-0.95). In patients with LVH, the rates of primary outcome were 3.21%/year with warfarin, 1.69% with dabigatran 110 mg (HR vs. warfarin 0.52, 95% CI 0.32-0.84) and 1.55% with 150 mg (HR vs. warfarin 0.48, 95% CI 0.29-0.78). The interaction between LVH status and dabigatran 110 mg vs. warfarin was significant for the primary outcome (P = 0.021) and stroke (P = 0.016). LVH was associated with a higher event rate with warfarin, not with dabigatran. In the warfari...Continue Reading
References
Oct 1, 1992·The Journal of Clinical Investigation·N A NelkenS R Coughlin
Jul 1, 1969·Annals of Internal Medicine·W B KannelD Offutt
May 15, 1981·Biochemical Pharmacology·D P Jones
Aug 22, 1996·The New England Journal of Medicine·E M HylekD E Singer
Jan 7, 1998·The American Journal of Cardiology·G Y LipD G Beevers
Feb 9, 2000·The Journal of Experimental Medicine·M A CunninghamP G Tipping
Apr 24, 2001·Japanese Circulation Journal·M KimuraM Matsuzaki
Oct 24, 2001·Circulation·P VerdecchiaG Ambrosio
Jul 25, 2003·American Journal of Hypertension·Paolo VerdecchiaGiuseppe Ambrosio
Mar 18, 2005·Heart·M JonesC J Currie
Jun 9, 2007·Current Opinion in Cardiology·Paolo VerdecchiaClaudio Cavallini
Jul 20, 2007·Hypertension·Gil F SallesElizabeth S Muxfeldt
Apr 21, 2009·American Heart Journal·Michael D EzekowitzSalim Yusuf
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Sep 19, 2009·Chest·Gregory Y H LipHarry J G M Crijns
Sep 23, 2009·Circulation·Paolo VerdecchiaUNKNOWN ONTARGET/TRANSCEND Investigators
Jan 1, 2010·The New England Journal of Medicine·Donald Stuart Houston, Ryan Zarychanski
Feb 12, 2011·Arthritis and Rheumatism·Galina S BogatkevichRichard M Silver
May 10, 2011·Biomedical Research·Yoshiyuki MoriguchiTakashi Nishimura
Jul 27, 2012·European Heart Journal Cardiovascular Imaging·Anita C BoydLiza Thomas
Feb 15, 2013·PloS One·Julian I BorissoffHugo ten Cate
Dec 24, 2013·The American Journal of Cardiology·Paolo VerdecchiaUNKNOWN RE-LY Study Investigators
Jan 5, 2014·Cardiovascular Research·Henri M H SpronkHugo Ten Cate
Mar 25, 2014·Heart and Vessels·Hideyuki KishimaTohru Masuyama
Jun 25, 2015·The Annals of Pharmacotherapy·Michaela del Campo, Greg Roberts
Aug 19, 2015·The American Journal of Cardiology·Rangadham NagarakantiMichael D Ezekowitz
Citations
Dec 22, 2017·F1000Research·Camilo R GomezJose Biller
Nov 2, 2018·Annals of Internal Medicine·Angela LowensternGillian D Sanders
Sep 1, 2019·BMJ Open·Ruijin QiuHongcai Shang
Dec 4, 2019·Journal of Thrombosis and Thrombolysis·Yunguo ZhouWengen Zhu
Sep 29, 2019·Acta Cardiologica·Pongprueth RujirachunPatompong Ungprasert
Dec 4, 2019·Circulation·Sarah MacIsaacRichard P Whitlock
Mar 5, 2021·Circulation. Arrhythmia and Electrophysiology·Sana M Al-KhatibChristopher B Granger